Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adjuvant endocrine therapy uptake, toxicity, quality of life, and prediction of early discontinuation.
Balazard F, Bertaut A, Bordet É, Mulard S, Blanc J, Briot N, Paux G, Dhaini Merimeche A, Rigal O, Coutant C, Fournier M, Jouannaud C, Soulie P, Lerebours F, Cottu PH, Tredan O, Vanlemmens L, Levy C, Mouret-Reynier MA, Campone M, Brady KJS, Sasane M, Rice M, Coulouvrat C, Martin AL, Jacquet A, Vaz-Luis I, Herold C, Pistilli B. Balazard F, et al. Among authors: lerebours f. J Natl Cancer Inst. 2023 Sep 7;115(9):1099-1108. doi: 10.1093/jnci/djad109. J Natl Cancer Inst. 2023. PMID: 37434306 Free PMC article.
Compliance to genomic test recommendations to guide adjuvant chemotherapy decision-making in the case of hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer, in real-life settings.
Hequet D, Hajjaji N, Charafe-Jauffret E, Boucrauta A, Dalenc F, Nicolai V, Lopez J, Tredan O, Deluche E, Fermeaux V, Tixier L, Cayre A, Menet E, Lerebours F, Rouzier R. Hequet D, et al. Among authors: lerebours f. Cancer Med. 2023 Aug;12(16):16889-16895. doi: 10.1002/cam4.6315. Epub 2023 Jul 6. Cancer Med. 2023. PMID: 37409516 Free PMC article.
[Rectal toxicity of Veganine suppositories: an unusual presentation].
Legallicier B, Parent B, Chamoun S, Duparc F, Lemoine F, Lerebours F, Colin R. Legallicier B, et al. Among authors: lerebours f. Gastroenterol Clin Biol. 1991;15(1):92-3. Gastroenterol Clin Biol. 1991. PMID: 2010078 French. No abstract available.
[Clinical activity spectrum of irinotecan].
Cottu PH, Extra JM, Lerebours F, Espie M, Marty M. Cottu PH, et al. Among authors: lerebours f. Bull Cancer. 1998 Dec;Spec No:21-5. Bull Cancer. 1998. PMID: 9932080 Free article. Review. French.
[Oxaliplatin: perspectives and future developments].
Marty M, Cottu PH, Lerebours F, Bedairia N, Hocini H, Espié M. Marty M, et al. Among authors: lerebours f. Bull Cancer. 2001 Aug;88 Spec No:S5-8. Bull Cancer. 2001. PMID: 11567907 French. No abstract available.
161 results